BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+0.51%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.85B
AUM Growth
+$9.85B
(-3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
226
New
13
Increased
56
Reduced
57
Closed
7
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$52.6M |
| 2 |
Revolution Medicines
RVMD
|
$44.1M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$37.4M |
| 4 |
Fate Therapeutics
FATE
|
$37M |
| 5 |
AMED
Amedisys
AMED
|
$36.1M |
Top Sells
| 1 |
Moderna
MRNA
|
$314M |
| 2 |
Halozyme
HALO
|
$53M |
| 3 |
Charles River Laboratories
CRL
|
$47.4M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$38M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$30.8M |
Sector Composition
| 1 | Healthcare | 96.84% |
| 2 | Industrials | 0.82% |
| 3 | Technology | 0.59% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Moderna
MRNA
$9.37B
| $665M | 6.75% | 1,727,349 -814,951 | -32% | -$314M |
|
2
Vertex Pharmaceuticals
VRTX
$100B
| $320M | 3.24% | 1,761,616 +27,922 | +2% | +$5.06M |
|
3
Ionis Pharmaceuticals
IONS
$6.79B
| $314M | 3.18% | 9,347,926 -582,319 | -6% | -$19.5M |
|
4
argenx
ARGX
$43.6B
| $297M | 3.02% | 983,938 +9,900 | +1% | +$2.99M |
|
5
Neurocrine Biosciences
NBIX
$13.8B
| $288M | 2.92% | 3,004,051 -13,700 | -0.5% | -$1.31M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $266M | 2.7% | 1,408,418 -140,674 | -9% | -$26.6M |
|
7
Incyte
INCY
$16.5B
| $203M | 2.06% | 2,957,000 -14,400 | -0.5% | -$990K |
|
8
Intuitive Surgical
ISRG
$170B
| $202M | 2.05% | 203,595 +1,500 | +0.7% | +$1.49M |
|
9
Agios Pharmaceuticals
AGIO
$2.19B
| $200M | 2.03% | 4,341,992 -11,000 | -0.3% | -$508K |
|
|
10
Fate Therapeutics
FATE
$120M
| $192M | 1.95% | 3,238,036 +624,500 | +24% | +$37M |
|
11
Arvinas
ARVN
$568M
| $184M | 1.87% | 2,241,403 +4,000 | +0.2% | +$329K |
|
12
MacroGenics
MGNX
$112M
| $179M | 1.82% | 8,544,597 +1,168,571 | +16% | +$24.5M |
|
13
Elevance Health
ELV
$71.8B
| $177M | 1.8% | 475,210 +9,234 | +2% | +$3.44M |
|
14
Abbott
ABT
$231B
| $164M | 1.66% | 1,387,499 +10,000 | +0.7% | +$1.18M |
|
15
Biogen
BIIB
$19.4B
| $149M | 1.51% | 527,000 -1,100 | -0.2% | -$311K |
|
16
DexCom
DXCM
$29.5B
| $144M | 1.46% | 263,839 +19,063 | +8% | +$10.4M |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $142M | 1.44% | 3,209,004 +844,800 | +36% | +$37.4M |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $141M | 1.43% | 3,773,919 +164,000 | +5% | +$6.11M |
|
19
Danaher
DHR
$147B
| $139M | 1.41% | 456,679 -26,261 | -5% | -$7.99M |
|
20
UnitedHealth
UNH
$281B
| $132M | 1.34% | 337,982 -5,069 | -1% | -$1.98M |
|
|
MYOV
21
DELISTED
Myovant Sciences Ltd.
MYOV
| $129M | 1.31% | 5,769,039 +500,000 | +9% | +$11.2M |
|
22
Boston Scientific
BSX
$156B
| $129M | 1.31% | 2,967,127 +640,340 | +28% | +$27.8M |
|
23
Tandem Diabetes Care
TNDM
$845M
| $124M | 1.25% | 1,034,519 +14,151 | +1% | +$1.69M |
|
24
Humana
HUM
$36.5B
| $122M | 1.24% | 312,762 +30,007 | +11% | +$11.7M |
|
25
Relay Therapeutics
RLAY
$619M
| $118M | 1.2% | 3,755,962 +1,115,000 | +42% | +$35.2M |
|